Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
XURA, INC. (MESG)
|
Add to portfolio |
|
|
|
| Price: |
$18.65
| | Metrics |
| OS: |
25.0
|
M
| |
74
|
% ROE
|
| Market cap: |
$467
|
M
| |
112
|
% ROIC
|
|
Net debt:
|
$180
|
M
| |
|
|
|
EV:
|
$646
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($68.5)
|
M
| |
|
|
|
EBIT
|
($75.4)
|
M
| |
|
|
| EPS |
$6.31
| |
3.0
|
x P/E
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Jan-31-16 | Jan-31-15 | Jan-31-14 | Jan-31-13 | Jan-31-12 | Jan-31-11 |
| Revenues | 270.9 | 269.0 | 416.0 | 677.8 | 771.2 | 862.8 |
| Revenue growth | 0.7% | -35.3% | -38.6% | -12.1% | -10.6% | |
| Cost of goods sold | 193.9 | 201.7 | 264.1 | 431.6 | 468.9 | 473.9 |
| Gross profit | 77.0 | 67.2 | 151.8 | 246.1 | 302.3 | 388.9 |
| Gross margin | 28.4% | 25.0% | 36.5% | 36.3% | 39.2% | 45.1% |
| Selling, general and administrative | 95.3 | 82.7 | 90.6 | 160.3 | 175.9 | 270.0 |
| Research and development | 37.3 | 36.9 | 39.4 | 76.5 | 94.2 | 148.8 |
| EBITA | -45.9 | -64.2 | 12.0 | 17.5 | 49.5 | -11.3 |
| EBITA margin | -16.9% | -23.9% | 2.9% | 2.6% | 6.4% | -1.3% |
| Amortization of intangibles | 22.5 | 0.2 | | 14.1 | 17.3 | 18.5 |
| EBIT | -68.4 | -64.4 | 12.0 | 3.4 | 32.2 | -29.8 |
| EBIT margin | -25.2% | -24.0% | 2.9% | 0.5% | 4.2% | -3.5% |
| Pre-tax income | -76.6 | -60.5 | 2.2 | -6.8 | 4.6 | -62.6 |
| Income taxes | -25.2 | -3.2 | 6.6 | 13.5 | 25.3 | 30.1 |
| Tax rate | 32.9% | 5.3% | 305.7% | | 544.7% | |
| Earnings from continuing ops | 132.8 | -79.4 | 18.7 | -21.5 | -23.2 | -93.8 |
| Earnings from discontinued ops | | | | 26.5 | 7.8 | 2.8 |
| Net income | 132.8 | -79.4 | 18.7 | 5.1 | -15.5 | -90.9 |
| Net margin | 49.0% | -29.5% | 4.5% | 0.7% | -2.0% | -10.5% |
| |
| Diluted EPS | $5.66 | ($3.58) | $0.84 | ($0.98) | ($1.06) | ($4.28) |
| Shares outstanding (diluted) | 23.5 | 22.2 | 22.2 | 21.9 | 21.9 | 21.9 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|